BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis_老虎社区_美港股上老虎

BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis

Reuters2021-02-23

Feb 23 (Reuters) - Ocugen Inc :

* EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

teokb989
·2021-02-23
[强]
回复
点赞
举报
ongyx
·2021-02-23
👍👍👍
回复
点赞
举报
seb59
·2021-02-23
🙏
回复
1
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2113335786?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-02-23 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2113335786","market":"us","top_or_hot":-1,"title":"BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis","media":"Reuters","content":"<html><body><p>Feb 23 (Reuters) - Ocugen Inc   :</p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-23 20:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2113335786","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2113335786","pubTimestamp":1614083671,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DES","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"简介-欧洲委员会授予Ocugen孤儿医药产品名称的基因治疗产品候选Ocu400，用于治疗视网膜色素变性和Leber先天性黑蒙症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSISSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":363900841,"gmtCreate":1614088374883,"gmtModify":1634551229883,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/363900841","repostId":2113335786,"repostType":2,"repost":{"id":"2113335786","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614083671,"share":"https://www.laohu8.com/m/news/2113335786?lang=&edition=full","pubTime":"2021-02-23 20:34","market":"us","language":"en","title":"BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2113335786","media":"Reuters","summary":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DES","content":"<html><body><p>Feb 23 (Reuters) - Ocugen Inc   :</p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-23 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Feb 23 (Reuters) - Ocugen Inc   :</p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2113335786","content_text":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSISSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":363049725,"gmtCreate":1614086420667,"gmtModify":1634551237356,"author":{"id":"3571394615915902","authorId":"3571394615915902","name":"ongyx","avatar":"https://static.tigerbbs.com/1c25a2544a6027a5f0d972b0748443b0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/363049725","repostId":2113335786,"repostType":2,"repost":{"id":"2113335786","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614083671,"share":"https://www.laohu8.com/m/news/2113335786?lang=&edition=full","pubTime":"2021-02-23 20:34","market":"us","language":"en","title":"BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2113335786","media":"Reuters","summary":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DES","content":"<html><body><p>Feb 23 (Reuters) - Ocugen Inc   :</p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-23 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Feb 23 (Reuters) - Ocugen Inc   :</p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2113335786","content_text":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSISSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":363023001,"gmtCreate":1614084747903,"gmtModify":1634551245274,"author":{"id":"3571385513122234","authorId":"3571385513122234","name":"seb59","avatar":"https://static.tigerbbs.com/1c43d56534d10cf52bf64cfe55f5e6e8","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"🙏","listText":"🙏","text":"🙏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/363023001","repostId":2113335786,"repostType":2,"repost":{"id":"2113335786","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614083671,"share":"https://www.laohu8.com/m/news/2113335786?lang=&edition=full","pubTime":"2021-02-23 20:34","market":"us","language":"en","title":"BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2113335786","media":"Reuters","summary":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DES","content":"<html><body><p>Feb 23 (Reuters) - Ocugen Inc   :</p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-23 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Feb 23 (Reuters) - Ocugen Inc   :</p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2113335786","content_text":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSISSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":3,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}